DEFERASIROX | A211383 | ZYDUS PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ZYDUS PHARMACEUTICALS (USA) INC. v. NOVARTIS PHARMACEUTICALS CORP. et al 1 patentANDA 211383deferasirox | D.N.J. | 2019-12-10 | Terminated 2020-02-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$1.50
per ea
Lowest NADAC/Unit
$0.8750
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70710127703DEFERASIROX 360 MG TABLET | $1.50 | EA | Generic | — | 2026-06-17 |
| 70710127603DEFERASIROX 180 MG TABLET | $0.8750 | EA | Generic | — | 2025-10-22 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.